BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co Acquisitions (Net)

The Acquisitions (Net) of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 22, 2026 is -182.94 M CNY. In the previous year, Acquisitions (Net) was -36.09 M CNY — a change of 406.91% (lower).

Acquisitions (Net)

-182.94 MCNY

YoY

406.91%

Last updated:

Acquisitions (Net) of BrightGene Bio-Medical Technology Co is 2024 -182.94 M CNY. Acquisitions (Net) of BrightGene Bio-Medical Technology Co was 2023 -36.09 M CNY. It decreases by 406.91% lower compared to the previous year.

The BrightGene Bio-Medical Technology Co Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2017
2.80 M CNY
Jan 1, 2018
-100.00 M CNY
Jan 1, 2019
-66.50 M CNY
Jan 1, 2020
-186.70 M CNY
Jan 1, 2021
19.82 M CNY
Jan 1, 2022
-144.85 M CNY
Jan 1, 2023
-36.09 M CNY
Jan 1, 2024
-182.94 M CNY
The BrightGene Bio-Medical Technology Co Acquisitions (Net) history
YEARAcquisitions (Net)YoY
-182.94 MCNY+406.91%
-36.09 MCNY-75.08%
-144.85 MCNY-830.66%
19.82 MCNY-110.62%
-186.70 MCNY+180.75%
-66.50 MCNY-33.50%
-100.00 MCNY-3,671.43%
2.80 MCNY—
0.00CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Acquisitions (Net) of BrightGene Bio-Medical Technology Co is -182.94 M CNY in 2024.

Acquisitions (Net) of BrightGene Bio-Medical Technology Co changed from -36.09 M CNY to -182.94 M CNY, representing a 406.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s BrightGene Bio-Medical Technology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BrightGene Bio-Medical Technology Co

All Key Metrics — BrightGene Bio-Medical Technology Co